{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:52:55Z","timestamp":1773273175744,"version":"3.50.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Acquired thrombotic thrombocytopenic purpura is an immune-mediated thrombotic microangiopathy caused by antibodies to ADAMTS13 (<jats:italic toggle=\"yes\">A D<\/jats:italic>isintegrin<jats:italic toggle=\"yes\">A<\/jats:italic>nd<jats:italic toggle=\"yes\">M<\/jats:italic>etalloproteinase with a<jats:italic toggle=\"yes\">T<\/jats:italic>hrombo<jats:italic toggle=\"yes\">S<\/jats:italic>pondin type 1 motif, member<jats:italic toggle=\"yes\">13<\/jats:italic>). Standard treatment with therapeutic plasma exchange and immunosuppression with steroids results in high remission and low mortality rates. However, a number of patients remain refractory to frontline therapy and\/or experience multiple relapses. This study reviews emerging therapies for thrombotic thrombocytopenic purpura.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Studies indicate that reducing anti-ADAMTS13 antibody levels through B-cell depletion or proteasome inhibition is effective for the management of refractory disease. Preliminary reports examining anti-CD20 therapy for the treatment of initial disease or as maintenance therapy for seropositive patients suggest the addition of immunosuppression in other disease phases may delay relapse. Exciting developments in targeted therapies to von Willebrand Factor and recombinant ADAMTS13 hold promise for transforming disease management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Approximately half of patients diagnosed with acquired thrombotic thrombocytopenic purpura experience refractory and\/or relapsing disease. For these patients, a hematologic remission may be an insufficient therapeutic goal. With recent developments, it is now possible to envision a multifaceted approach targeting disease mechanisms that may dramatically improve outcomes for this otherwise debilitating disease.<\/jats:p><\/jats:sec>","DOI":"10.1097\/moh.0000000000000375","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T14:45:34Z","timestamp":1501253134000},"page":"521-528","source":"Crossref","is-referenced-by-count":2,"title":["Novel therapeutic approaches for thrombotic thrombocytopenic purpura"],"prefix":"10.1097","volume":"24","author":[{"given":"Yvette C.","family":"Tanhehco","sequence":"first","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowthami","family":"Arepally","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ara","family":"Metjian","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.20669","article-title":"New-onset and idiopathic thrombotic thrombocytopenic purpura: incidence, diagnostic validity, and potential risk factors","volume":"81","author":"Schech","year":"2006","journal-title":"Am J Hematol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","author":"Rock","year":"1991","journal-title":"N Engl J MedV 325"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s002770050012","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases","volume":"79","author":"Dervenoulas","year":"2000","journal-title":"Ann Hematol"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"R11-20230917","first-page":"2023","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood 2013"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1537-2995.2007.01074.x","article-title":"Comparison and stability of ADAMTS13 activity in therapeutic plasma products","volume":"47","author":"Scott","year":"2007","journal-title":"Transfusion"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jca.2920100404","article-title":"Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura","volume":"10","author":"Owens","year":"1995","journal-title":"J Clin Apher"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21336","article-title":"Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation","volume":"29","author":"Stefanello","year":"2014","journal-title":"J Clin Apher"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21288","article-title":"The use of 50% albumin\/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura","volume":"28","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Apher"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000264996","article-title":"Efficacy and Safety Profile of Solvent\/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience","volume":"37","author":"Edel","year":"2010","journal-title":"Transfus Med Hemother"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/trf.13877","article-title":"A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent\/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy","volume":"57","author":"Vendramin","year":"2017","journal-title":"Transfusion"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"Mintz","year":"2006","journal-title":"Transfusion"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","article-title":"Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Soucemarianadin","year":"2016","journal-title":"Eur J Haematol"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"},{"key":"R23-20230917","first-page":"325","article-title":"Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP","volume":"80","author":"Centurioni","year":"1995","journal-title":"Haematologica"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000046567","article-title":"Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases","volume":"105","author":"Dervenoulas","year":"2001","journal-title":"Acta Haematol"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","article-title":"Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature","volume":"45","author":"Ziman","year":"2005","journal-title":"Transfusion"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.transci.2016.12.019","article-title":"Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms","volume":"56","author":"Coppo","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminhematol.2010.01.010","article-title":"Rituximab in autoimmune hematologic diseases: not just a matter of B cells","volume":"47","author":"Stasi","year":"2010","journal-title":"Semin Hematol"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejim.2015.07.021","article-title":"French reference center for thrombotic M: rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story","volume":"26","author":"Froissart","year":"2015","journal-title":"Eur J Intern Med"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura","volume":"10","author":"Bettoni","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"R40-20230917","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010816.pub2","article-title":"Bortezomib for the treatment of multiple myeloma","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","article-title":"An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"136","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood.V128.22.133.133","article-title":"A prospective, randomized study of cyclosporine or corticosteroids as an adjunct to plasma exchange for the treatment of thrombotic thrombocytopenic purpura","author":"Cataland","year":"2016","journal-title":"Blood"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.2003.04183.x","article-title":"ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13","volume":"120","author":"Antoine","year":"2003","journal-title":"Br J Haematol"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/jth.13137","article-title":"Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13","volume":"13","author":"Plaimauer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jth.13341","article-title":"Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Kopic","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood.V128.22.135.135","article-title":"Pharmacodynamic profile of a recombinant ADAMTS13 (BAX930) in hereditary thrombotic thrombocytopenic purpura (Upshaw\u2013Schulman Syndrome (USS))","volume":"128","author":"Scully","year":"2016","journal-title":"Blood"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion"},{"key":"R57-20230917","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"e1277","DOI":"10.1097\/MJT.0000000000000386","article-title":"N-acetylcysteine for relapsing thrombotic thrombocytopenic purpura: more evidence of a promising drug","volume":"23","author":"Cabanillas","year":"2016","journal-title":"Am J Ther"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/trf.12787","article-title":"N-acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?","volume":"54","author":"Shortt","year":"2014","journal-title":"Transfusion"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00062752-201711000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:40:05Z","timestamp":1750790405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00062752-201711000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000375","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}